TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
Stopped The supporting pharamceutical company elected not to pursue this study at this time.
Conditions
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- DRUG: Group 1: TK216
- DRUG: Group 2: TK216
- DRUG: Part 2: Decitabine 10mg/m2
- DRUG: Part 2: Decitabine 20 mg/m2
- DRUG: Expansion Phase TK216
- DRUG: Expansion Phase Decitabine
- DRUG: Part 2: TK216
Sponsor
M.D. Anderson Cancer Center
Collaborators